Serum VEGF Predicts Worse Clinical Outcome of Patients with Coronary Heart Disease After Percutaneous Coronary Intervention Therapy

摘要

BACKGROUND Percutaneous coronary intervention (PCI) is an effective treatment for coronary heart disease (CHD) patients. However, patients after PCI treatment often have ischemic events that result in poor prognosis. Our study aimed to investigate the effects of vascular endothelial growth factor (VEGF) level on the prognosis of CHD patients. MATERIAL AND METHODS We enrolled 114 CHD patients in the study. Serum [i]VEGF[/i] level was measured by enzyme-linked immunosorbent assay (ELISA). Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and Hs-CRP were also tested in patients. The patients were divided into 2 groups according to the level of [i]VEGF[/i]. Kaplan-Meier curve was used to observe the differences in survival situation of patients of the 2 groups. Cox regression analysis was conducted to judge whether [i]VEGF[/i] was an independent biomarker for prognosis in CHD. RESULTS We included 104 patients for survival analysis. [i]VEGF[/i] level in CHD patients was significantly lower than that of healthy individuals ([i]P[/i]<0.05). In the analysis of basic information, we found differences in sex distribution and hypertension between groups ([i]P[/i]<0.05 for both). Kaplan-Meier curve indicated that patients with low expression of [i]VEGF[/i] presented with poor prognosis. The mortality rate of the low-expression group was 37.71%, higher than that of the high-expression group (14.3%). Cox analysis suggested that [i]VEGF[/i] could serve as a biomarker for prognosis in CHD (HR: 3.014, [i]P[/i]: 0.019). CONCLUSIONS Low level of [i]VEGF[/i] may predict poor clinical outcome of CHD patients after PCI treatment.